Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
The company said the journal published two-year follow-up data from its Phase 2 RAMP 201 study of AVMAPKI FAKZYNJA CO-PACK in recurrent low-grade serous ovarian cancer. Verastem cited median duration of response of 31.1 months and no new safety signals.
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Gynecologic Oncology, the official journal of the Society of Gynecologic Oncology (SGO), has published two-year long-term results…